<![CDATA[ AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)]]>https://aidsinfo.nih.gov/e-news/archive60<![CDATA[HHS Pediatric Antiretroviral Treatment Guidelines Updated]]>https://aidsinfo.nih.gov/e-news/archive/2018/5/22

The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has released an updated version of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.


Some of the key guideline updates include:
  • In the Introduction, the Panel describes the process of coordinating with the authors of the Perinatal Guidelines to jointly develop the three sections of the Pediatric Antiretroviral (ARV) Treatment Guidelines that are shared with the Perinatal Guidelines.
  • The Panel now recommends performing viral load measurements every 3 to 4 months to monitor antiretroviral therapy (ART) adherence and disease progression. The list of bulleted recommendations in Clinical and Laboratory Monitoring of Pediatric HIV Infection has been updated to reflect this change.
  • The recommendations in When to Initiate Therapy in Antiretroviral-Naive Children have been revised. The Panel now recommends that all children receive ART, regardless of symptoms or CD4 T lymphocyte count.
  • An additional column and footnotes indicating which drugs are available in fixed-dose combination (FDC) formulations were added to Table 7 in What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children.
  • Didanosine and stavudine are no longer recommended for use in ARV regimens, due to the significant toxicities of these drugs and the availability of safer agents. Table 9 and Table 10 in What Not to Start: Regimens Not Recommended for Initial Therapy of Antiretroviral-Naive Children have been updated accordingly.
  • Considerations About Interruptions in Antiretroviral Therapy now includes issues that may contribute to interrupted treatment in children from limited resource settings and emphasizes the need to plan for potential interruptions.
  • A number of the drug sections in Appendix A: Pediatric Antiretroviral Drug Information now include new pediatric data and dosing and safety information, as well as new drug formulations and FDCs.

For a complete list of guideline updates, please see What's New in the Guidelines. Additions and revisions are also highlighted in yellow throughout the PDF version of the guidelines.


To view or download the guidelines, go to the Pediatric ARV Guidelines section of AIDSinfo. Separate PDF files that contain only the guideline tables or the boxed recommendations can also be downloaded from the page.


Send Comments on the Revised Guidelines to AIDSinfo

Feedback on the revised Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection is welcome. Please email your comments with the subject line “Comments on the Pediatric ARV Guidelines” to ContactUs@aidsinfo.nih.gov by June 5, 2018.

 

 

]]>
Tue, 22 May 2018 00:00:00 GMT
<![CDATA[AIDSinfo Highlights Two May HIV/AIDS Awareness Days]]>https://aidsinfo.nih.gov/e-news/archive/2018/5/17
May 18: HIV Vaccine Awareness Day

HIV Vaccine Awareness Day is an occasion to highlight HIV vaccine research and recognize the many volunteers, community members, health professionals, and scientists involved in this important research. To learn more, visit the AIDSinfo HIV Vaccine Awareness Day webpage [en español].


May 19: National Asian and Pacific Islander HIV/AIDS Awareness Day

National Asian and Pacific Islander HIV/AIDS Awareness Day was founded to end the silence and shame surrounding HIV and AIDS in Asian and Pacific Islander communities in the United States and to encourage community members to get tested for HIV. To learn more, browse the AIDSinfo National Asian and Pacific Islander HIV/AIDS Awareness Day webpage [en español].

 

]]>
Thu, 17 May 2018 00:00:00 GMT
<![CDATA[ Recent HIV News from NIH]]>https://aidsinfo.nih.gov/e-news/archive/2018/5/17
  • May 7, 2018: NIH Clinical Trial to Track Outcomes of Kidney Transplantation from HIV-Positive Donors to HIV-Positive Recipients
  • ]]>
    Thu, 17 May 2018 00:00:00 GMT
    <![CDATA[Visit AIDSinfo to Explore Information on Investigational HIV Drugs]]>https://aidsinfo.nih.gov/e-news/archive/2018/5/3Are you looking for information on HIV medicines that are in development, also called investigational drugs? AIDSinfo provides fact sheets for more than 60 investigational HIV drugs and vaccines. These drugs and vaccines are currently being studied in clinical trials and are not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States to treat or prevent HIV.

    AIDSinfo provides information for both patients and health professionals: a patient fact sheet includes an overview of the drug and information on clinical trials studying the drug, and a health professional fact sheet includes more detailed, scientific information about the drug, including information on the pharmacology of the drug and on adverse events identified in clinical trials.

    The latest investigational fact sheets that have been added to the AIDSinfo Drug Database include VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP, both of which are therapeutic HIV vaccines. The lefitolimod, romidepsin, and VAC-3S fact sheets have recently been updated based on research that was presented at the Conference on Retroviruses and Opportunistic Infections (CROI).

    Do you want to learn more about investigational HIV drugs and vaccines? Check out the AIDSinfo What is an Investigational HIV Drug? fact sheet and use the AIDSinfo Drug Database filters to search for investigational drugs and vaccines.

     

    ]]>
    Thu, 3 May 2018 00:00:00 GMT
    <![CDATA[ Recent HIV News from NIH]]>https://aidsinfo.nih.gov/e-news/archive/2018/5/3
  • April 25, 2018: Anti-HIV Drug Combination Does Not Increase Preterm Birth Risk, Study Suggests
  • ]]>
    Thu, 3 May 2018 00:00:00 GMT
    <![CDATA[AIDSinfo Releases Fact Sheets on Three New HIV Medications]]>https://aidsinfo.nih.gov/e-news/archive/2018/4/19
    Click on the fact sheets below to learn about each medicine, including possible side effects: Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet and infographic.

     

    ]]>
    Thu, 19 Apr 2018 00:00:00 GMT
    <![CDATA[ AIDSinfo Updates Consumer Fact Sheets]]>https://aidsinfo.nih.gov/e-news/archive/2018/4/19info consumer fact sheets provide important information on how HIV affects different groups of people. Each fact sheet includes a summary of key points and links to additional information and resources.

    View the updated fact sheets: Visit infoSIDA to view the fact sheets in Spanish.

     

    ]]>
    Thu, 19 Apr 2018 00:00:00 GMT
    <![CDATA[ Recent HIV News from NIAID]]>https://aidsinfo.nih.gov/e-news/archive/2018/4/19
  • April 16, 2018: Genetically Altered Broadly Neutralizing Antibodies Protect Monkeys from HIV-Like Virus
  • ]]>
    Thu, 19 Apr 2018 00:00:00 GMT